KR102287226B1 - 신규한 펩타이드 및 이를 유효성분으로 포함하는 안구질환 치료용 약학 조성물 - Google Patents

신규한 펩타이드 및 이를 유효성분으로 포함하는 안구질환 치료용 약학 조성물 Download PDF

Info

Publication number
KR102287226B1
KR102287226B1 KR1020180056745A KR20180056745A KR102287226B1 KR 102287226 B1 KR102287226 B1 KR 102287226B1 KR 1020180056745 A KR1020180056745 A KR 1020180056745A KR 20180056745 A KR20180056745 A KR 20180056745A KR 102287226 B1 KR102287226 B1 KR 102287226B1
Authority
KR
South Korea
Prior art keywords
gly
leu
yde
ala
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020180056745A
Other languages
English (en)
Korean (ko)
Other versions
KR20180126406A (ko
Inventor
백태곤
김택수
임대성
구득영
Original Assignee
주식회사 유유제약
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 유유제약 filed Critical 주식회사 유유제약
Publication of KR20180126406A publication Critical patent/KR20180126406A/ko
Priority to KR1020210100394A priority Critical patent/KR102498428B1/ko
Application granted granted Critical
Publication of KR102287226B1 publication Critical patent/KR102287226B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y10S514/912—

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020180056745A 2017-05-17 2018-05-17 신규한 펩타이드 및 이를 유효성분으로 포함하는 안구질환 치료용 약학 조성물 Active KR102287226B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020210100394A KR102498428B1 (ko) 2017-05-17 2021-07-30 신규한 펩타이드 및 이를 유효성분으로 포함하는 안구질환 치료용 약학 조성물

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170061250 2017-05-17
KR1020170061250 2017-05-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020210100394A Division KR102498428B1 (ko) 2017-05-17 2021-07-30 신규한 펩타이드 및 이를 유효성분으로 포함하는 안구질환 치료용 약학 조성물

Publications (2)

Publication Number Publication Date
KR20180126406A KR20180126406A (ko) 2018-11-27
KR102287226B1 true KR102287226B1 (ko) 2021-08-11

Family

ID=64566301

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020180056745A Active KR102287226B1 (ko) 2017-05-17 2018-05-17 신규한 펩타이드 및 이를 유효성분으로 포함하는 안구질환 치료용 약학 조성물
KR1020210100394A Active KR102498428B1 (ko) 2017-05-17 2021-07-30 신규한 펩타이드 및 이를 유효성분으로 포함하는 안구질환 치료용 약학 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020210100394A Active KR102498428B1 (ko) 2017-05-17 2021-07-30 신규한 펩타이드 및 이를 유효성분으로 포함하는 안구질환 치료용 약학 조성물

Country Status (13)

Country Link
US (1) US12037415B2 (https=)
EP (1) EP3643723B1 (https=)
JP (2) JP7680824B2 (https=)
KR (2) KR102287226B1 (https=)
CN (1) CN110945012A (https=)
AU (1) AU2018281617B2 (https=)
BR (1) BR112019024040A2 (https=)
CA (1) CA3063842A1 (https=)
ES (1) ES2982308T3 (https=)
MX (1) MX2019013799A (https=)
RU (1) RU2766160C2 (https=)
SG (1) SG11201912110YA (https=)
WO (1) WO2018225961A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210097670A (ko) * 2017-05-17 2021-08-09 주식회사 유유제약 신규한 펩타이드 및 이를 유효성분으로 포함하는 안구질환 치료용 약학 조성물

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11613558B2 (en) 2018-11-14 2023-03-28 Yuyu Pharma, Inc. Peptides and pharmaceutical compositions for treating eye diseases
TWI865470B (zh) * 2018-11-14 2024-12-11 南韓商柳柳製藥股份有限公司 治療眼睛疾病之肽及醫藥組合物
JP7576048B2 (ja) * 2019-05-21 2024-10-30 アイバイオ コリア 新規なペプチド化合物またはその薬学的に許容される塩
KR20210104460A (ko) * 2020-02-17 2021-08-25 주식회사 아이바이오코리아 고체상 합성법을 이용한 펩타이드의 제조 방법
EP4114430A4 (en) * 2020-03-05 2025-05-14 YUYU Pharma, Inc. TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS
KR102593936B1 (ko) * 2021-12-13 2023-10-27 주식회사 아이바이오코리아 신규한 펩타이드를 포함하는 황반변성의 치료용 조성물
AU2022412618B2 (en) * 2021-12-13 2026-02-19 Eyebiokorea, Inc. Composition for treating macular degeneration comprising novel peptide
KR102587729B1 (ko) * 2023-02-27 2023-10-12 주식회사 아이바이오코리아 펩타이드를 포함하는 당뇨망막병증의 치료용 조성물
KR102673860B1 (ko) * 2023-08-10 2024-06-12 (주)케어젠 안구 건조증의 개선 활성을 갖는 펩타이드 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101690539B1 (ko) 2015-07-30 2016-12-29 주식회사 아이바이오코리아 건성안 예방 또는 치료용 약학조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
WO2007117444A2 (en) * 2006-03-31 2007-10-18 Yinghe Hu Protein detection by aptamers
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
US20090131303A1 (en) * 2007-11-16 2009-05-21 Bor-Shyue Hong Methods and compositions for treating dry eye
JP4490498B2 (ja) 2008-09-30 2010-06-23 新田ゼラチン株式会社 疾病抑制剤
CA2836946C (en) * 2011-05-27 2017-08-01 Allergan, Inc. A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof
MX2014006399A (es) * 2011-11-30 2015-04-10 Xigen Inflammation Ltd Uso de inhibidores de peptidos con celulas permeables de la via para transduccion de señal de jnk para el tratamiento de la queratoconjuntivitis seca.
KR101438744B1 (ko) * 2012-08-02 2014-09-15 전남대학교산학협력단 아디포넥틴을 유효성분으로 포함하는 안구건조증 또는 염증성 안구표면 질환의 예방 또는 치료용 조성물
KR101555296B1 (ko) 2013-12-10 2015-09-23 인제대학교 산학협력단 연골세포 유래 세포외 기질을 유효성분으로 함유하는 건성안 예방 또는 치료용 약학조성물
KR101948156B1 (ko) 2013-12-10 2019-02-14 인제대학교 산학협력단 알칼리 화상을 이용한 각막 혼탁증 동물모델 및 각막 혼탁증 예방 또는 치료용 약학조성물
KR101721059B1 (ko) 2014-12-26 2017-03-30 주식회사 아이바이오코리아 안구 표면 질환 예방 또는 치료용 약학조성물
TWI675851B (zh) 2015-12-14 2019-11-01 台灣基督長老教會馬偕醫療財團法人馬偕紀念醫院 短合成胜肽及其用途
CN109310731B (zh) * 2016-04-08 2022-03-29 韩国视角生物株式会社 软骨细胞的细胞外基质来源的肽
KR101798183B1 (ko) * 2016-04-08 2017-11-15 주식회사 아이바이오코리아 건성안 예방 또는 치료용 약학조성물
KR101795653B1 (ko) 2016-05-19 2017-11-09 인제대학교 산학협력단 콜라겐 타입 ii 펩타이드-아플리버셉트의 키메라 단백질을 유효성분으로 함유하는 혈관신생 억제용 조성물
KR20180074928A (ko) 2016-12-26 2018-07-04 주식회사 아이바이오코리아 건성안 예방 또는 치료용 동물 의약품 조성물
KR102287226B1 (ko) 2017-05-17 2021-08-11 주식회사 유유제약 신규한 펩타이드 및 이를 유효성분으로 포함하는 안구질환 치료용 약학 조성물
TWI865470B (zh) * 2018-11-14 2024-12-11 南韓商柳柳製藥股份有限公司 治療眼睛疾病之肽及醫藥組合物
US11613558B2 (en) 2018-11-14 2023-03-28 Yuyu Pharma, Inc. Peptides and pharmaceutical compositions for treating eye diseases
EP4114430A4 (en) * 2020-03-05 2025-05-14 YUYU Pharma, Inc. TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101690539B1 (ko) 2015-07-30 2016-12-29 주식회사 아이바이오코리아 건성안 예방 또는 치료용 약학조성물

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210097670A (ko) * 2017-05-17 2021-08-09 주식회사 유유제약 신규한 펩타이드 및 이를 유효성분으로 포함하는 안구질환 치료용 약학 조성물
KR102498428B1 (ko) * 2017-05-17 2023-02-20 주식회사 유유제약 신규한 펩타이드 및 이를 유효성분으로 포함하는 안구질환 치료용 약학 조성물

Also Published As

Publication number Publication date
AU2018281617B2 (en) 2022-06-30
SG11201912110YA (en) 2020-01-30
EP3643723B1 (en) 2024-05-15
RU2019141646A3 (https=) 2021-07-28
ES2982308T3 (es) 2024-10-15
JP2023098936A (ja) 2023-07-11
RU2019141646A (ru) 2021-06-17
JP2020520372A (ja) 2020-07-09
CN110945012A (zh) 2020-03-31
US12037415B2 (en) 2024-07-16
BR112019024040A2 (pt) 2020-09-24
US20210024577A1 (en) 2021-01-28
RU2766160C2 (ru) 2022-02-08
EP3643723C0 (en) 2024-05-15
MX2019013799A (es) 2020-08-13
KR102498428B1 (ko) 2023-02-20
EP3643723A1 (en) 2020-04-29
CA3063842A1 (en) 2019-12-09
AU2018281617A1 (en) 2019-12-05
KR20210097670A (ko) 2021-08-09
EP3643723A4 (en) 2021-03-31
WO2018225961A1 (ko) 2018-12-13
KR20180126406A (ko) 2018-11-27
JP7775250B2 (ja) 2025-11-25
JP7680824B2 (ja) 2025-05-21

Similar Documents

Publication Publication Date Title
KR102498428B1 (ko) 신규한 펩타이드 및 이를 유효성분으로 포함하는 안구질환 치료용 약학 조성물
CN103435570B (zh) 治疗剂的药代动力学特性调节剂
JP7522732B2 (ja) 眼疾患治療用のペプチド及び医薬組成物
US20160058733A1 (en) Cdc7 kinase inhibitors and uses thereof
PT2231628E (pt) Inibidores de citocromo p450
CN103328497A (zh) 环孢菌素类似物
EP4114430A2 (en) Treatment of inflammatory diseases with peptides and pharmaceutical compositions
CN106589055A (zh) 取代的细胞酰二肽类化合物及其制备方法和用途
CN119708106A (zh) 甾体化合物及其应用
WO2025061048A1 (zh) 甾体化合物及其应用
CN119661620A (zh) 甾体化合物及其应用
WO2021088839A1 (zh) 咪唑烷酮类化合物及其制备方法与应用
CA3119921C (en) Peptides and pharmaceutical compositions for treating eye diseases
RU2819399C2 (ru) Пептиды и фармацевтические композиции для лечения глазных болезней
HK40017864A (en) Novel peptide and pharmaceutical composition for treatment of eye diseases comprising same novel peptide as active ingredient
HK40061089B (zh) 用於治疗眼病的肽和药物组合物
CN109734712A (zh) 芳基或杂芳基取代的吡咯烷酰胺衍生物及其用途
HK40061089A (en) Peptides and pharmaceutical compositions for treating eye diseases
WO2026012523A2 (zh) 钠通道调节剂
NZ739511B2 (en) Pyrazole pyrimidine derivative and uses thereof

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0107 Divisional application

St.27 status event code: A-0-1-A10-A18-div-PA0107

St.27 status event code: A-0-1-A10-A16-div-PA0107

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5